Skip to main content
Erschienen in: Pediatric Nephrology 7/2006

01.07.2006 | Original Article

Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury

verfasst von: Howard Trachtman, Erica Christen, Avital Cnaan, Jilma Patrick, Volker Mai, Jaya Mishra, Aditya Jain, Nathan Bullington, Prasad Devarajan, Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial

Erschienen in: Pediatric Nephrology | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Background: Diarrhea-associated hemolytic uremic syndrome (D+HUS) causes acute renal failure. Neutrophil gelatinase-associated lipocalcin (NGAL) is an early indicator of kidney injury. Objective: To determine if urinary NGAL excretion is a biomarker of severe renal injury and predicts the need for dialysis in D+HUS. Methods: Patients were randomly selected from among participants in the SYNSORB Pk trial. Urine samples were collected daily if available during the first week of hospitalization. NGAL levels were determined by ELISA. Results: 34 children, age 5.9±3.9 yr, were studied; ten (29%) required dialysis. Patients were categorized based on urinary NGAL concentration within five days of hospitalization - <200 ng/ml and ≥200 ng/ml. Twenty patients (58%) had increased urinary NGAL excretion. The severity of D+HUS at enrollment was similar in the two groups. However, children with increased urinary NGAL levels had higher peak BUN and creatinine concentrations (P<0.01) and required dialysis more often, 9/20 versus 1/14 (P=0.024) compared to children with normal excretion. Conclusion: The majority of patients with D+HUS have renal tubular epithelial injury, as evidenced by elevated urinary NGAL excretion. Urinary NGAL levels below 200 ng/ml within five days of hospitalization may be an adjunctive marker that defines less severe renal involvement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Trachtman H, Christen C (1999) Hemolytic uremic syndrome: current understanding of the pathogenesis and therapeutic trials and interventions. Curr Opin Pediatr 11:162–168CrossRef Trachtman H, Christen C (1999) Hemolytic uremic syndrome: current understanding of the pathogenesis and therapeutic trials and interventions. Curr Opin Pediatr 11:162–168CrossRef
2.
Zurück zum Zitat Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086PubMed Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086PubMed
3.
Zurück zum Zitat Kaplan BA, Meyers KE, Schulman S (1998) The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9:1126–1133PubMed Kaplan BA, Meyers KE, Schulman S (1998) The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9:1126–1133PubMed
4.
Zurück zum Zitat Andreoli SP, Trachtman H, Acheson DWK, Siegler RL, Obrig TG (2002) Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 17:293–298CrossRef Andreoli SP, Trachtman H, Acheson DWK, Siegler RL, Obrig TG (2002) Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 17:293–298CrossRef
5.
Zurück zum Zitat Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DWK, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH (2003) Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: A randomized clinical trial. JAMA 290:1337–1344CrossRef Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DWK, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH (2003) Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: A randomized clinical trial. JAMA 290:1337–1344CrossRef
6.
Zurück zum Zitat Siegler RL (1994) Spectrum of extra-renal involvement in postdiarrheal hemolytic–uremic syndrome. J Pediatr 125:511–518CrossRef Siegler RL (1994) Spectrum of extra-renal involvement in postdiarrheal hemolytic–uremic syndrome. J Pediatr 125:511–518CrossRef
7.
Zurück zum Zitat Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370CrossRef Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370CrossRef
8.
Zurück zum Zitat Ray PE, Liu XH (2001) Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 16:823–839CrossRef Ray PE, Liu XH (2001) Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 16:823–839CrossRef
9.
Zurück zum Zitat Kiyokawa N, Taguchi T, Mori T, Uchida H, Sato N, Takeda T, Fujimoto J (1998) Induction of apoptosis in normal renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 178:178–184CrossRef Kiyokawa N, Taguchi T, Mori T, Uchida H, Sato N, Takeda T, Fujimoto J (1998) Induction of apoptosis in normal renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 178:178–184CrossRef
10.
Zurück zum Zitat Hughes AK, Stricklett PK, Kohan DE (1998) Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 54:426–437CrossRef Hughes AK, Stricklett PK, Kohan DE (1998) Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 54:426–437CrossRef
11.
Zurück zum Zitat Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050CrossRef Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050CrossRef
12.
Zurück zum Zitat Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalcin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543CrossRef Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalcin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543CrossRef
13.
Zurück zum Zitat Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P (2004) Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalcin. J Am Soc Nephrol 15:3073–3082CrossRef Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P (2004) Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalcin. J Am Soc Nephrol 15:3073–3082CrossRef
14.
Zurück zum Zitat Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J (2005) Endocytic delivery of lipocalcin–siderophore–iron complex rescues the kidney ischemia–reperfusion injury. J Clin Invest 115:610–621CrossRef Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J (2005) Endocytic delivery of lipocalcin–siderophore–iron complex rescues the kidney ischemia–reperfusion injury. J Clin Invest 115:610–621CrossRef
15.
Zurück zum Zitat Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalcin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238CrossRef Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalcin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238CrossRef
16.
Zurück zum Zitat Te Loo DM, Monnens LA, van den Heuvel LP, Gubler MC, Kockx MM (2001) Detection of apoptosis in kidney biopsies of patients with D+ hemolytic uremic syndrome. Pediatr Res 49:413–416CrossRef Te Loo DM, Monnens LA, van den Heuvel LP, Gubler MC, Kockx MM (2001) Detection of apoptosis in kidney biopsies of patients with D+ hemolytic uremic syndrome. Pediatr Res 49:413–416CrossRef
17.
Zurück zum Zitat Nestoridi E, Kushak RI, Duguerre D, Grabowski EF, Ingelfinger JR (2005) Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 67:2254–2266CrossRef Nestoridi E, Kushak RI, Duguerre D, Grabowski EF, Ingelfinger JR (2005) Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 67:2254–2266CrossRef
18.
Zurück zum Zitat Schulman SL, Kaplan BS (1996) Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria. Pediatr Nephrol 10:671–674CrossRef Schulman SL, Kaplan BS (1996) Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria. Pediatr Nephrol 10:671–674CrossRef
19.
Zurück zum Zitat Lameire N, Van Biesen W, Vanholder R (2005) Acute renal failure. Lancet 365:417–430CrossRef Lameire N, Van Biesen W, Vanholder R (2005) Acute renal failure. Lancet 365:417–430CrossRef
20.
Zurück zum Zitat Ohlsson S, Wieslander J, Segelmark M (2003) Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin Exp Immunol 131:528–535CrossRef Ohlsson S, Wieslander J, Segelmark M (2003) Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin Exp Immunol 131:528–535CrossRef
Metadaten
Titel
Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury
verfasst von
Howard Trachtman
Erica Christen
Avital Cnaan
Jilma Patrick
Volker Mai
Jaya Mishra
Aditya Jain
Nathan Bullington
Prasad Devarajan
Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial
Publikationsdatum
01.07.2006
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 7/2006
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-006-0146-y

Weitere Artikel der Ausgabe 7/2006

Pediatric Nephrology 7/2006 Zur Ausgabe

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.